Castle Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-155
Closed -$12K 648
2022
Q3
$12K Hold
155
0.01% 402
2022
Q2
$12K Buy
+155
New +$11.6K 0.01% 381

Other funds holding XBI

Castle Wealth Management's XBI Position: Q4 2022 in Review

Castle Wealth Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2022, closing a stake of 155 shares — an estimated $12K sold.

Castle Wealth Management first reported a position in XBI in Q2 2022 and held it in 2 quarters. The position peaked at $12K in Q3 2022. 746 funds tracked by Wall St. Rank hold XBI as of Q4 2022.

  • Castle Wealth Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2022 after selling out during the quarter.
  • Castle Wealth Management sold 155 State Street SPDR S&P Biotech ETF shares in Q4 2022, an estimated $12K.
  • Castle Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 2 quarters.
  • Castle Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $12K in Q3 2022.
  • 746 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2022.

Based on Castle Wealth Management's 13F filing for Q4 2022, filed 9 Feb 2023.